首页> 外国专利> LIGANDS FOR INTEGRIN amp;#x26;#945;Vamp;#x26;#946;8, SYNTHESIS AND USES THEREOF

LIGANDS FOR INTEGRIN amp;#x26;#945;Vamp;#x26;#946;8, SYNTHESIS AND USES THEREOF

机译:整合剂α Vβ 8的合成及其用途

摘要

Disclosed are compounds represented by the following general formula (I): Cyclo-(Arg-Gly-Asp-X1-X2-X2-X4-X5) (I) wherein the variables groups X1 to X5 have the following meanings X1: Leu, Ile, Nle, Val, Tyr, Phe; X2: D-amino acid such as D-Pro, N-Me-D-Phe; X3: Pro, N-Me-amino acid such as N-Me-Lys, N-Me-Lys(Ac); Pro-Rx3, N-Me-Lys-Rx4; X4: Gly, Ala, Ser, Thr; X5: Leu, Ala, Tyr, His, Ile, Nle, Val, Phe wherein Pro-Rx3 represents a proline residue that carries at the C-3, C-4 or C-5 carbon atom and preferably the C-4 carbon atom a functional group selected from —NH2, —OH, —NH—Ac, —NH-hexyne, and wherein Lys-Rx4 represents a lysine residue, wherein the ω-amino nitrogen atom carries a group of the formula -L4-R4, wherein L4 is selected from the group consisting of covalent bond, —C(O)—, and —C(O)—O—, . . . , and wherein R4 is selected from the group consisting of —(CH2)n-C≡CH with n=0, 1, 2, 3, 4, 5, 6, 7 or 8, or wherein the sub-sequence -X2-X3- represents a β-turn mimetic diffeωωring from the meanings above, or pharmaceutically acceptable salts, esters, solvates, polymorphs or modified forms thereof represented by the following general formula (II): (X0)n1L(X8)n2 wherein X0 represents the compound of the general formula (I) as specified above (excluding one hydrogen atom to allow bonding to the linker), L represents a linker, X8 represents the effector moiety and wherein n1 and n2 are each independently selected from the range of 1 to 5, preferably such that each of n1 and n2 represents 1, wherein n1+n2 represents the number of valencies of the linker and is preferably in the range of from 2 to 6, more preferably 2-5, with the proviso that each of n1 and n2 is at least 1, as well as uses therefore in therapy and imaging.
机译:公开了由以下通式(I)表示的化合物:环-(Arg-Gly-Asp-X 1 -X 2 -X 2 -X 4 -X 5 )(I),其中变量组X 1 至X 5 具有以下含义X 1 :Leu,Ile,Nle,Val,Tyr,Phe; X 2 :D-氨基酸,例如D-Pro,N-Me-D-Phe; X 3 :Pro,N-Me-氨基酸,例如N-Me-Lys,N-Me-Lys(Ac); Pro-Rx3,N-Me-Lys-Rx4; X 4 :Gly,Ala,Ser,Thr; X 5 :Leu,Ala,Tyr,His,Ile,Nle,Val,Phe,其中Pro-Rx3代表在C-3,C-4或C-5碳原子上携带的脯氨酸残基C 4碳原子优选为选自以下的官能团:— NH2,— OH,— NH— Ac,— NH-己炔,其中Lys-R x4 代表赖氨酸残基,其中ω-氨基氮原子带有式-L4-R4的基团,其中L4选自共价键— C(O)& #x2014;和— C(O)— O&#x2014 ;,。 。 。 ,并且其中R4选自n = 0、1、2、3、4、5、6、7或8的(CH2)n-C≡ CH,或其中-序列-X 2 -X 3 -表示具有上述含义的β-转角模拟差异,或其药学上可接受的盐,酯,溶剂化物,多晶型物或修饰形式由以下通式(II)表示:(X 0 n1 L(X 8 n2 其中X0代表上述通式(I)的化合物(不包括一个氢原子以允许与连接基键合),L代表连接基,X 8代表效应子部分,其中n 1和n 2为各自独立地选自1至5的范围,优选使得n1和n2各自代表1,其中n1 + n2代表连接基的化合价数,并且优选地在2至6的范围内,更优选地2-参见图5,其中n1和n2中的每一个至少为1,并且为此使用e在治疗和成像方面。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号